These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3391625)

  • 1. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1988 May; 7(3):273-6. PubMed ID: 3391625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metoprolol alpha-hydroxylation polymorphism in the San Bushmen of southern Africa.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1989 Jan; 8(1):39-43. PubMed ID: 2714809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1989 Sep; 8(5):365-8. PubMed ID: 2807305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
    Du YL; Lou YQ
    Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
    Wanwimolruk S; Patamasucon P; Lee EJ
    Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians.
    Woolhouse NM; Andoh B; Mahgoub A; Sloan TP; Idle JR; Smith RL
    Clin Pharmacol Ther; 1979 Nov; 26(5):584-91. PubMed ID: 498701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diurnal effects on debrisoquine hydroxylation phenotyping.
    Lee EJ
    Eur J Clin Pharmacol; 1988; 35(4):441-2. PubMed ID: 3197754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
    Alván G; Grind M; Graffner C; Sjöqvist F
    Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
    Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically determined oxidation capacity and the disposition of debrisoquine.
    Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
    Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphic ochratoxin A hydroxylation in rat strains phenotyped as poor and extensive metabolizers of debrisoquine.
    Castegnaro M; Bartsch H; Bereziat JC; Arvela P; Michelon J; Broussolle L
    Xenobiotica; 1989 Feb; 19(2):225-30. PubMed ID: 2786290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphism of debrisoquine hydroxylation among Finns and Lapps.
    Arvela P; Kirjarinta M; Kirjarinta M; Kärki N; Pelkonen O
    Br J Clin Pharmacol; 1988 Nov; 26(5):601-3. PubMed ID: 3207564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study on the frequency distribution of debrisoquine hydroxylation deficiency in Chinese healthy Zang and Wei volunteers].
    Kuang TY; Liao XM; Wang KY; Zhang Y; Lou YQ
    Yao Xue Xue Bao; 1991; 26(4):250-4. PubMed ID: 1957669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interethnic dissociation between debrisoquine and desipramine hydroxylation.
    Rudorfer MV; Lane EA; Potter WZ
    J Clin Psychopharmacol; 1985 Apr; 5(2):89-92. PubMed ID: 3988975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Debrisoquine hydroxylation polymorphism in diabetic patients.
    Kallio J; Huupponen R; Viikari J
    Diabetes Res; 1990 Nov; 15(3):125-9. PubMed ID: 2132205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The metabolism of debrisoquine in man: (1) regioselectivity of hydroxylation and (2) aberrant oxidative metabolism in two sibling patients with carbimazole-induced agranulocytosis.
    Ritchie JC; Crothers MJ; Shah RR; Idle JR; Smith RL
    Xenobiotica; 1986 May; 16(5):503-9. PubMed ID: 3739370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine.
    Eichelbaum M; Bertilsson L; Küpfer A; Steiner E; Meese CO
    Br J Clin Pharmacol; 1988 Apr; 25(4):505-8. PubMed ID: 3382592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.
    Caporaso N; Pickle LW; Bale S; Ayesh R; Hetzel M; Idle J
    Genet Epidemiol; 1989; 6(4):517-24. PubMed ID: 2777072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary bile acid and bile alcohol excretion does not reflect the genetic polymorphism of debrisoquine hydroxylation.
    Karlaganis G; Küpfer A; Preisig R
    Br J Clin Pharmacol; 1984 Apr; 17(4):470-3. PubMed ID: 6721994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.